# A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients

> **NCT04350177** · PHASE1 · COMPLETED · sponsor: **ABLi Therapeutics, Inc.** · enrollment: 101 (actual)

## Conditions studied

- Healthy Elderly
- Parkinson Disease

## Interventions

- **DRUG:** IkT-148009
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04350177
- **Lead sponsor:** ABLi Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-16
- **Primary completion:** 2022-10-30
- **Final completion:** 2023-01-30
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04350177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04350177, "A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04350177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*